Zhengye Biotechnology (ZYBT) Competitors $2.44 -0.08 (-3.17%) As of 10/24/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ZYBT vs. CRVS, ARCT, ADCT, ORGO, INBX, MBX, ETON, ALMS, ATXS, and FULCShould you be buying Zhengye Biotechnology stock or one of its competitors? The main competitors of Zhengye Biotechnology include Corvus Pharmaceuticals (CRVS), Arcturus Therapeutics (ARCT), ADC Therapeutics (ADCT), Organogenesis (ORGO), Inhibrx Biosciences (INBX), MBX Biosciences (MBX), Eton Pharmaceuticals (ETON), Alumis (ALMS), Astria Therapeutics (ATXS), and Fulcrum Therapeutics (FULC). These companies are all part of the "pharmaceutical products" industry. Zhengye Biotechnology vs. Its Competitors Corvus Pharmaceuticals Arcturus Therapeutics ADC Therapeutics Organogenesis Inhibrx Biosciences MBX Biosciences Eton Pharmaceuticals Alumis Astria Therapeutics Fulcrum Therapeutics Corvus Pharmaceuticals (NASDAQ:CRVS) and Zhengye Biotechnology (NASDAQ:ZYBT) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment, risk and earnings. Which has stronger valuation and earnings, CRVS or ZYBT? Zhengye Biotechnology has higher revenue and earnings than Corvus Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCorvus PharmaceuticalsN/AN/A-$62.29M-$1.01-7.28Zhengye Biotechnology$25.53M4.51$1.55MN/AN/A Do institutionals & insiders have more ownership in CRVS or ZYBT? 46.6% of Corvus Pharmaceuticals shares are held by institutional investors. 28.5% of Corvus Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Is CRVS or ZYBT more profitable? Zhengye Biotechnology's return on equity of 0.00% beat Corvus Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Corvus PharmaceuticalsN/A -28.61% -18.05% Zhengye Biotechnology N/A N/A N/A Do analysts rate CRVS or ZYBT? Corvus Pharmaceuticals presently has a consensus target price of $13.75, suggesting a potential upside of 87.07%. Given Corvus Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Corvus Pharmaceuticals is more favorable than Zhengye Biotechnology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Corvus Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60Zhengye Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Does the media refer more to CRVS or ZYBT? In the previous week, Corvus Pharmaceuticals had 2 more articles in the media than Zhengye Biotechnology. MarketBeat recorded 3 mentions for Corvus Pharmaceuticals and 1 mentions for Zhengye Biotechnology. Zhengye Biotechnology's average media sentiment score of 1.89 beat Corvus Pharmaceuticals' score of 0.63 indicating that Zhengye Biotechnology is being referred to more favorably in the news media. Company Overall Sentiment Corvus Pharmaceuticals Positive Zhengye Biotechnology Very Positive SummaryCorvus Pharmaceuticals beats Zhengye Biotechnology on 6 of the 11 factors compared between the two stocks. Get Zhengye Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for ZYBT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ZYBT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZYBT vs. The Competition Export to ExcelMetricZhengye BiotechnologyMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$118.86M$3.43B$6.24B$10.66BDividend YieldN/A2.27%5.71%4.82%P/E RatioN/A25.3030.4630.37Price / Sales4.51510.44595.13134.23Price / Cash24.4645.5737.0161.44Price / Book2.3910.4012.046.60Net Income$1.55M-$52.62M$3.32B$276.82M7 Day Performance-8.27%2.09%1.88%2.53%1 Month Performance-18.67%12.32%7.68%3.71%1 Year PerformanceN/A14.12%56.01%33.82% Zhengye Biotechnology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZYBTZhengye BiotechnologyN/A$2.44-3.2%N/AN/A$118.86M$25.53M0.00278Positive NewsGap DownCRVSCorvus Pharmaceuticals2.0794 of 5 stars$7.04-1.0%$13.75+95.3%-4.3%$529.79MN/A-6.9730Analyst ForecastGap DownARCTArcturus Therapeutics3.4594 of 5 stars$21.25+9.6%$50.57+138.0%-40.9%$526.54M$109.80M-9.53180Trending NewsAnalyst DowngradeAnalyst RevisionADCTADC Therapeutics2.4038 of 5 stars$4.11-11.0%$7.75+88.8%+41.1%$518.62M$70.84M-2.61310News CoverageAnalyst ForecastGap DownORGOOrganogenesis3.8826 of 5 stars$4.00+1.3%$7.33+83.3%+48.4%$501.09M$482.04M-28.57950Gap DownINBXInhibrx Biosciences2.0544 of 5 stars$34.81+1.3%N/A+272.7%$498.01M$200K-3.29166Trending NewsGap UpMBXMBX Biosciences3.5181 of 5 stars$13.52-6.8%$42.80+216.6%N/A$487.11MN/A-2.98N/APositive NewsInsider TradeETONEton Pharmaceuticals2.5 of 5 stars$18.77+3.8%$29.67+58.1%+125.4%$484.86M$39.01M-117.3120News CoverageALMSAlumis3.2728 of 5 stars$4.63+0.4%$20.17+335.6%-62.3%$479.74MN/A0.00N/ANews CoveragePositive NewsAnalyst ForecastATXSAstria Therapeutics1.8782 of 5 stars$11.61+37.1%$25.00+115.3%+6.5%$478MN/A-5.7830Analyst ForecastHigh Trading VolumeFULCFulcrum Therapeutics2.4804 of 5 stars$8.69-0.7%$9.60+10.5%+184.6%$473.30M$80M-7.12100Analyst ForecastAnalyst Revision Related Companies and Tools Related Companies CRVS Alternatives ARCT Alternatives ADCT Alternatives ORGO Alternatives INBX Alternatives MBX Alternatives ETON Alternatives ALMS Alternatives ATXS Alternatives FULC Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ZYBT) was last updated on 10/25/2025 by MarketBeat.com Staff From Our PartnersNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zhengye Biotechnology Holding Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Zhengye Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ZYBT Stock Alerts